Navigation Links
JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares
Date:6/2/2009

NEW YORK, June 2 /PRNewswire/ -- JLL Partners, Inc. and its affiliate, JLL Patheon Holdings, LLC (collectively, "JLL"), announced today that as at 6:00 p.m. (Toronto time) on June 1, 2009 (the "Expiry Time") a total of 33,667,752 Restricted Voting Shares in the capital of Patheon Inc. ("Patheon") have been validly deposited to JLL's offer to acquire, at a price of US$2.00 cash per Restricted Voting Share, all of the issued and outstanding Restricted Voting Shares of Patheon (the "Offer"). As all of the conditions of the Offer have been met, JLL has taken up and made payment to the Depository for all of the Restricted Voting Shares validly deposited as of the Expiry Time. Payment will be made on or before Thursday, June 4, 2009 to Patheon shareholders who have validly deposited their Restricted Voting Shares under the Offer since May 19, 2009.

The Restricted Voting Shares taken up since the Offer was launched represent approximately 38% of the outstanding Restricted Voting Shares of Patheon not already owned by JLL or its affiliates and associates. Together with the Restricted Voting Shares owned prior to the Offer, JLL or its affiliates and associates now own 35,317,752 Restricted Voting Shares of Patheon or approximately 39% of the outstanding Restricted Voting Shares of Patheon. JLL also holds 150,000 convertible preferred shares convertible into Restricted Voting Shares representing approximately 29% of the currently issued and outstanding Restricted Voting Shares on an as-converted basis. If JLL were to convert its convertible preferred shares, which it is free to do at any time, it would hold in the aggregate 57% of the total number of Restricted Voting Shares issued and outstanding and would be entitled to vote such securities at any shareholders meeting. JLL will continue to assess whether or not to convert its convertible preferred shares as facts and circumstances develop.

JLL also announced that it has extended the Offer which will now expire ten days from the mailing of a formal notice of extension. JLL expects to mail a formal notice of extension to Patheon shareholders shortly. JLL intends to take up and pay for any further Restricted Voting Shares as and when they are deposited.

About JLL Partners

JLL Partners, Inc. is a New York-based leading private equity investment firm with approximately $4.0 billion of capital under management. JLL's investment philosophy is to partner with outstanding management teams and invest with them in companies that they can continue to grow into market leaders. JLL has invested in a variety of industries, with special focus on financial services, building products, and healthcare services and medical products. More information on JLL can be found on the website www.jllpartners.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements that involve risks and uncertainties. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "expected", "scheduled", "estimates", "intends", "anticipates", or "believes", or variations of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. These forward-looking statements reflect JLL's best judgment based on current information, factors and assumptions, and although it bases these statements on circumstances that it believes to be reasonable when made, there can be no assurance that future events will not affect the accuracy of such forward-looking information. As such, the forward-looking statements are not guarantees of future performance or actions, and actual performance and actions may vary materially from the actions and expectations discussed in this documentation. JLL disclaims any intention or obligation to update or revise any forward looking information whether as a result of new information, future events or otherwise, except as required by applicable law.

    The Information Agent for the          The Dealer Manager for the
     Offer is:                              Offer is:

    Laurel Hill Advisory Group             UBS Securities Canada Inc.
    366 Bay Street, Suite 200              161 Bay Street
    Toronto, ON  M5H 4B2                   Suite 4100, P.O. Box 617
    Telephone Toll Free (North             Toronto, ON  M5J 2S1
     America):(888) 290-1555               Telephone: (416) 350-2201
    Telephone Collect (outside North
     America): (416) 637-4661


'/>"/>
SOURCE JLL Partners
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Resource for Those Living with Hepatitis C Announces Website Redesign
2. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
3. Immucor Announces Fiscal Year 2010 Guidance
4. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
5. ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
6. Michael J. Fox Foundation Announces Launch of PD Online Research
7. Roshan Announces Expansion of Afghanistans First Telemedicine Project to Bamyan Region
8. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
9. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
10. Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic
11. MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and ... Odds” is the creation of published author, Walter Hubbard, a retired wildlife and fisheries ... child Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... York, New York (PRWEB) , ... May 24, 2017 , ... ... general vascular surgery in New York City. He is known for his ... broad specialization in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Manju R. Kejriwal, ... ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal understands the emotional and ... convenient, clear braces in Cincinnati, OH. Patients no longer need to feel the esthetic ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As ... latest advancements in his field by attending numerous CE courses each year. His ...
(Date:5/24/2017)... ... ... are thinking of a visit to San Francisco , fall is a great time ... visit. , Business Architecture Associates is pleased to offer 5 days of training courses, available ... package for individuals, and as 4-½ day corporate package for up to 3 employees with ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... 2017 MACRA replaces the outdated sustainable ... service reimbursement. Black Book Research crowdsource-surveyed 8,845 physician practices ... The Market for MIPS Compliance Technology is Booming ... with 3 or more clinicians seek to buy Merit-Based ... the magnitude of the changes, the hunt is on ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
(Date:5/4/2017)... , May 4, 2017  A recent ... Control, Ultraviolet-C light as a means ... SmartUVC,s ability to reduce bioburden on anesthesia workstations. ... reduction on high-touch, complex medical equipment surfaces contaminated ... infections. "This study further validates the ...
Breaking Medicine Technology: